133 related articles for article (PubMed ID: 27775427)
1. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Biomarkers; 2017 Mar; 22(2):157-164. PubMed ID: 27775427
[TBL] [Abstract][Full Text] [Related]
2. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
4. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Zajkowska M; Gacuta E; Kozłowska S; Lubowicka E; Głażewska EK; Chrostek L; Szmitkowski M; Pawłowski P; Zbucka-Krętowska M; Ławicki S
Adv Med Sci; 2019 Mar; 64(1):1-8. PubMed ID: 30227310
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Onco Targets Ther; 2016; 9():911-9. PubMed ID: 26966379
[TBL] [Abstract][Full Text] [Related]
7. VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.
Ławicki S; Będkowska GE; Szmitkowski M
Growth Factors; 2013 Jun; 31(3):98-105. PubMed ID: 23688065
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
[TBL] [Abstract][Full Text] [Related]
9. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.
Zajkowska M; Głażewska EK; Będkowska GE; Chorąży P; Szmitkowski M; Ławicki S
Mediators Inflamm; 2016; 2016():5962946. PubMed ID: 27445439
[TBL] [Abstract][Full Text] [Related]
11. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
12. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
13. [The plasma levels and diagnostic utility of selected hematopoietic growth factors (HGFs) in breast cancer patients].
Ławicki S; Czygier M; Wojtukiewicz M; Szmitkowski M
Przegl Lek; 2010; 67(12):1314-8. PubMed ID: 21591359
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer.
Mroczko B; Lukaszewicz-Zając M; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2011; 49(1):125-31. PubMed ID: 21526499
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
19. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
20. [The plasma levels and diagnostic utility of granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage - colony stimulating factor (GM-CSF) in patients with I and II stage of breast cancer].
Ławicki S; Czygier M; Wojtukiewicz M; Szmitkowski M
Przegl Lek; 2009; 66(7):365-9. PubMed ID: 20043577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
